Extended Data Fig. 3: Proportion of patients achieving PASI 75 response at week 12 and week 24 (ITT-NRI). | Nature Medicine

Extended Data Fig. 3: Proportion of patients achieving PASI 75 response at week 12 and week 24 (ITT-NRI).

From: Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Extended Data Fig. 3: Proportion of patients achieving PASI 75 response at week 12 and week 24 (ITT-NRI).

**P < 0.01; ***P < 0.001 vs. placebo. Two-sided P-values were estimated using a logistic regression model including fixed effects for treatment and stratification factors (sex and prior biologic exposure). Statistical analyses for these endpoints were exploratory, and P-values are nominal (no adjustments to P-values or significance levels were performed). NRI, except for part B for patients who switched treatment due to a lack of joint response or for patients in the USA who completed the study at week 12, where the last observation during part A was carried forward. Percentage based on patients with ≥3% BSA at baseline in the ITT population. ADA ref, adalimumab reference; BSA, body surface area; ITT, intention-to-treat; NI, no induction; NRI, non-responder imputation; PASI, Psoriasis Area and Severity Index; PBO, placebo; PsO, psoriasis; SLK, sonelokimab; WI, with induction.

Back to article page